GO:0048156 tau protein binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048156 (tau protein binding) is a molecular function describing the selective interaction of a protein with tau, a microtubule-associated protein implicated in Alzheimer's disease, Down syndrome and ALS.
• Tau binding is central to tau physiology: it governs tau's association with microtubules, its aggregation into tangles, and its clearance by chaperones and the ubiquitin-proteasome system.
• The microtubule-binding repeat (MTBR) domain of tau is the principal interaction surface for many tau-binding proteins and for therapeutic antibodies such as E2814.
• Phosphorylation of tau, especially at a single residue, can inhibit binding to the E3 ubiquitin ligase CHIP, linking tau phosphorylation to impaired degradation.
• Tau-binding proteins include kinases (e.g., GSK3B, CDK5), phosphatases (e.g., PPP2CA), chaperones (e.g., HSPA8), ubiquitin ligases (e.g., STUB1/CHIP), and cytoskeletal proteins (e.g., MAP1A, MAP2).
• CRISPR-based knockout, point-mutation, knock-in and overexpression models are essential to dissect which tau interactions are causal in neurodegeneration versus compensatory.
Description
Tau protein binding (GO:0048156) is a molecular function defined as the selective interaction of a protein with tau, a microtubule-associated protein that is implicated in Alzheimer's disease, Down syndrome and amyotrophic lateral sclerosis (ALS). Tau is best known for stabilizing microtubules in axons, but it also participates in a wide range of protein-protein interactions that regulate its localization, phosphorylation, aggregation and degradation. The term tau protein binding captures these interactions and is therefore central to understanding both normal neuronal physiology and tauopathies. Researchers study tau protein binding to identify the molecular partners that drive tau pathology, to map the tau interactome in healthy and diseased brain, and to develop therapeutics that block pathological tau interactions. Because tau binding is dynamically regulated by post-translational modifications, especially phosphorylation, it sits at the intersection of signaling, proteostasis and neurodegeneration. This article summarizes the authoritative GO definition, the biological processes and molecular mechanisms of tau protein binding, the key genes and proteins involved, and the experimental models and methods used to study it.
tau protein binding At A Glance
| GO ID | GO:0048156 |
|---|---|
| GO term | tau protein binding |
| Ontology | molecular_function |
| Synonym | None |
| Definition | Binding to tau protein. tau is a microtubule-associated protein, implicated in Alzheimer's disease, Down Syndrome and ALS. |
| Major function | Mediates physical interaction with tau, influencing its localization, stability, aggregation and clearance. |
| Related diseases | Alzheimer's disease, frontotemporal dementia, Down syndrome, ALS |
| Key domains | Microtubule-binding repeat (MTBR) domain of tau is a common interaction surface |
| Regulation | Phosphorylation of tau can inhibit binding to E3 ubiquitin ligase CHIP |
What Is GO:0048156?
In the Gene Ontology, GO:0048156 (tau protein binding) is a molecular function term that describes the binding of a protein to tau protein. Tau is a microtubule-associated protein that is implicated in Alzheimer's disease, Down syndrome and ALS. The term is used to annotate gene products that physically interact with tau, whether the interaction is direct or part of a larger complex. It does not specify the functional consequence of binding (e.g., stabilization, degradation, aggregation), only the binding event itself. The term has no synonyms in QuickGO.
Why Is tau protein binding Important in Cell Biology?
Tau protein binding is important because tau's pathological aggregation into neurofibrillary tangles is a hallmark of Alzheimer's disease and other tauopathies, and the interactions that tau makes with other proteins determine whether tau is properly cleared or becomes toxic. Understanding tau protein binding helps explain how tau is regulated in health and how this regulation fails in disease, and it provides a roadmap for therapeutic strategies that target tau interactions, such as passive immunotherapy against the microtubule-binding region.
• Tau binding is required for tau's normal association with microtubules and for axonal transport.
• Tau-binding proteins such as kinases and phosphatases regulate tau phosphorylation, a key driver of pathology.
• The E3 ubiquitin ligase CHIP binds tau and targets it for degradation; phosphorylation of tau at a single residue inhibits this binding.
• Tau interactome studies in human Alzheimer's disease brain reveal disease-specific binding partners.
• CSF tau microtubule-binding region fragments reflect tangle pathology and clinical stages of Alzheimer's disease.
• Antibodies targeting the tau microtubule-binding repeat domain, such as E2814, are in clinical development for Alzheimer's disease.
• Tau binding is implicated in frontotemporal dementia, Down syndrome and ALS.
• CRISPR models of tau-binding partners can distinguish causal from correlative interactions.
Molecular Mechanism of tau protein binding
Tau domain architecture and interaction surfaces
In simple terms: Tau has a sticky region that many other proteins grab onto.
Tau is an intrinsically disordered protein with a microtubule-binding repeat (MTBR) domain that serves as a major interaction surface for many tau-binding proteins. The MTBR domain is also the region that forms the core of tau filaments in Alzheimer's disease, making it a hotspot for both physiological and pathological interactions. Antibodies such as E2814 have been developed to bind this domain with high affinity, demonstrating that the MTBR is accessible and targetable.
Phosphorylation-dependent regulation of tau binding
In simple terms: Adding phosphate groups to tau can change who it binds to.
Phosphorylation of tau is a major regulator of its interactions. For example, phosphorylation of tau at a single residue inhibits its binding to the E3 ubiquitin ligase CHIP, thereby reducing tau ubiquitination and degradation. This provides a direct link between tau phosphorylation, tau protein binding and proteostasis. Phosphorylated tau interactome studies in human Alzheimer's disease brain have identified disease-associated binding partners that are enriched in phospho-tau complexes.
Tau binding to cytoskeletal and motor proteins
In simple terms: Tau binds to the cell's skeleton and transport machinery.
Tau binds to microtubules and to other microtubule-associated proteins, contributing to cytoskeletal stability and axonal transport. These interactions are essential for neuronal function, and their disruption is an early event in tauopathies. The microtubule-binding region of tau is also the target of CSF biomarkers that reflect tangle pathology.
Tau binding to chaperones and degradation machinery
In simple terms: Tau interacts with helper proteins that decide whether it is recycled or destroyed.
Tau interacts with molecular chaperones such as HSPA8 and with ubiquitin ligases such as CHIP (STUB1), which mediate its folding and degradation. Phosphorylation of tau at a specific residue inhibits CHIP binding, impairing tau clearance and promoting its accumulation. These interactions are critical for maintaining tau homeostasis and are disrupted in Alzheimer's disease.
Tau binding in disease: aggregation and spreading
In simple terms: When tau binds the wrong partners, it can clump and spread.
In tauopathies, tau undergoes conformational changes that promote its aggregation into filaments. The MTBR domain is central to this process, and tau-binding proteins can either promote or inhibit aggregation. CSF tau microtubule-binding region fragments are emerging as biomarkers that identify tau tangle and clinical stages of Alzheimer's disease. Frontotemporal dementia is another tauopathy where tau binding and aggregation play a central role.
Key Genes Involved in GO:0048156 tau protein binding
The following genes and proteins are among the most studied in the context of tau protein binding, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAPT | Encodes tau protein; provides the binding target for GO:0048156 | Central to tauopathies; mutations cause frontotemporal dementia |
| STUB1 (CHIP) | E3 ubiquitin ligase that binds tau and targets it for degradation | Phosphorylation of tau inhibits CHIP binding |
| GSK3B | Kinase that phosphorylates tau | Regulates tau binding to microtubules and other partners |
| CDK5 | Kinase that phosphorylates tau | Implicated in tau hyperphosphorylation |
| PPP2CA | Phosphatase that dephosphorylates tau | Modulates tau binding interactions |
| HSPA8 | Chaperone that binds tau | Involved in tau folding and clearance |
| MAP1A | Microtubule-associated protein that interacts with tau | Cytoskeletal cross-linking |
| MAP2 | Microtubule-associated protein that interacts with tau | Dendritic cytoskeleton regulation |
| FYN | Kinase that binds tau | Links tau to synaptic signaling |
| PIN1 | Peptidyl-prolyl isomerase that binds phosphorylated tau | Regulates tau conformation |
| BAG3 | Co-chaperone involved in tau clearance | Modulates tau proteostasis |
| CHMP2B | ESCRT-III component linked to tau | Frontotemporal dementia |
| VCP | AAA-ATPase that interacts with tau | Protein quality control |
| SQSTM1 (p62) | Autophagy receptor that binds tau | Tau clearance |
| UBQLN2 | Ubiquilin that binds tau | ALS and FTD |
| E2814 target | Antibody targeting MTBR of tau | Passive immunotherapy |
| MTBR | Microtubule-binding repeat domain of tau | Key interaction surface |
How Is tau protein binding Regulated?
Tau protein binding is regulated by post-translational modifications of tau, especially phosphorylation. Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase CHIP, reducing tau ubiquitination and degradation. Kinases such as GSK3B and CDK5, and phosphatases such as PPP2CA, modulate tau phosphorylation and thereby its interactions. The phosphorylated tau interactome in Alzheimer's disease brain reveals disease-specific binding partners, indicating that regulation is altered in disease. Additionally, the microtubule-binding region of tau is subject to proteolytic processing, generating CSF fragments that reflect tangle pathology.
tau protein binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MAPT | Alzheimer's disease, frontotemporal dementia | Knockout and knock-in mice; human iPSC-derived neurons |
| STUB1 (CHIP) | Tau degradation; Alzheimer's disease | Point mutation at tau phosphorylation site to block CHIP binding |
| GSK3B | Tau hyperphosphorylation | Overexpression and knockout cell models |
| E2814 target (MTBR) | Alzheimer's disease immunotherapy | Antibody binding assays; tau aggregation models |
| MTBR fragments | CSF biomarkers for Alzheimer's disease | Clinical cohort studies |
Alzheimer's disease
Alzheimer's disease is characterized by tau tangles, and tau protein binding is central to tau aggregation and spreading. CSF tau microtubule-binding region fragments identify tau tangle and clinical stages of Alzheimer's disease. Phosphorylated tau interactome studies in human brain reveal disease-specific binding partners. Antibodies targeting the MTBR domain, such as E2814, are being developed for passive immunotherapy.
Frontotemporal dementia
Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder often linked to tau pathology. Mutations in MAPT cause familial FTD, and tau protein binding interactions are disrupted. Understanding tau binding in FTD may reveal therapeutic targets.
Down syndrome and ALS
Tau is implicated in Down syndrome and amyotrophic lateral sclerosis (ALS), where tau protein binding may contribute to neurodegeneration. The GO definition explicitly mentions these diseases, highlighting the broad relevance of tau interactions.
From tau protein binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate tau-binding protein alter tau aggregation? | CRISPR knockout in human iPSC-derived neurons or HEK293T cells |
| Does phosphorylation at a specific tau residue block CHIP binding? | Point mutation of tau at the phosphorylation site (e.g., T231A) |
| Can a disease-associated mutation in MAPT be corrected? | Knock-in of wild-type MAPT using CRISPR |
| Where does a tau-binding protein localize in neurons? | Tagged knock-in of the binding protein with fluorescent tag |
| Does overexpression of a tau-binding protein exacerbate tau pathology? | Overexpression of the binding protein in tau transgenic models |
| Which tau interactions are altered in Alzheimer's disease brain? | Phosphorylated tau interactome from human brain tissue |
How to Study the tau protein binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Physical interaction between tau and candidate proteins | Validation of tau-binding partners |
| Mass spectrometry | Tau interactome composition | Discovery of disease-specific tau binders |
| Phospho-tau interactome | Binding partners of phosphorylated tau | Alzheimer's disease brain studies |
| In vitro binding assay | Direct binding affinity and competition | Testing phosphorylation effects on CHIP binding |
| CSF immunoassay | MTBR tau fragment levels | Clinical staging of Alzheimer's disease |
| Antibody binding assay | Epitope accessibility on tau | Development of therapeutic antibodies like E2814 |
| CRISPR knockout | Loss-of-function of tau-binding genes | Causal testing in cell models |
| Proximity ligation assay | In situ interaction between tau and partners | Neuronal localization studies |
Affinity purification and mass spectrometry
Affinity purification of tau followed by mass spectrometry identifies tau-binding proteins in cell lysates and tissues. This approach has been used to map the phosphorylated tau interactome in human Alzheimer's disease brain, revealing disease-specific binding partners.
Co-immunoprecipitation and proximity ligation
Co-immunoprecipitation and proximity ligation assays confirm direct or close interactions between tau and candidate proteins. These methods are useful for validating interactions identified by proteomics.
Phosphorylation-specific binding assays
In vitro binding assays using phosphorylated and unphosphorylated tau can determine how phosphorylation regulates interactions. For example, phosphorylation of tau at a single residue inhibits binding to CHIP.
CSF biomarker assays
CSF tau microtubule-binding region fragments can be measured by immunoassays to identify tau tangle and clinical stages of Alzheimer's disease.
How CRISPR Can Be Used to Study GO:0048156 tau protein binding
Knockout
CRISPR knockout of genes encoding tau-binding proteins can determine whether the interaction is required for tau aggregation, clearance or toxicity. For example, knocking out STUB1 (CHIP) would test its role in tau degradation. Knockout of MAPT itself eliminates tau and provides a clean background for studying tau-binding partners.
Point Mutation
Point mutations can be introduced into tau to block specific phosphorylation sites or interaction interfaces. For instance, mutating the phosphorylation site that inhibits CHIP binding would test the consequence of constitutive CHIP binding. Point mutations in MAPT that cause frontotemporal dementia can be modeled to study altered tau binding.
Knock-in
Knock-in of disease-associated mutations or tags into the endogenous MAPT locus allows study of tau binding under physiological expression levels. Tagged knock-in of tau with a fluorescent or affinity tag enables interaction studies in neurons.
Overexpression
Overexpression of tau or its binding partners can exacerbate or rescue tau pathology in cell and animal models. Overexpression of kinases such as GSK3B increases tau phosphorylation and alters its binding profile.
How EDITGENE Supports tau protein binding Research
Researchers studying tau protein binding-related genes often need to determine whether a candidate gene is causally involved in tau pathology or simply correlated with it. EDITGENE provides CRISPR-based cell models and screening services to enable these causal experiments.
Contact EDITGENE today to design your custom CRISPR model for tau protein binding research.
Frequently Asked Questions About tau protein binding
What is GO:0048156 tau protein binding?
GO:0048156 is a Gene Ontology molecular function term defined as binding to tau protein, a microtubule-associated protein implicated in Alzheimer's disease, Down syndrome and ALS.
What genes are involved in tau protein binding?
Key genes include MAPT (tau), STUB1 (CHIP), GSK3B, CDK5, PPP2CA, HSPA8, MAP1A, MAP2, FYN, PIN1, BAG3, VCP, SQSTM1 and UBQLN2.
How is tau protein binding regulated?
Tau protein binding is regulated by phosphorylation; for example, phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase CHIP.
What diseases are associated with tau protein binding?
Alzheimer's disease, frontotemporal dementia, Down syndrome and ALS are associated with tau protein binding.
What is the microtubule-binding region of tau?
The microtubule-binding repeat (MTBR) domain is a key interaction surface on tau and the target of therapeutic antibodies such as E2814.
How can I study tau protein binding in the lab?
Common methods include co-immunoprecipitation, mass spectrometry, in vitro binding assays, CSF immunoassays and CRISPR knockout models.
What is the role of CHIP in tau protein binding?
CHIP is an E3 ubiquitin ligase that binds tau and targets it for degradation; phosphorylation of tau inhibits this binding.
Can CRISPR be used to study tau protein binding?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are widely used to dissect tau interactions.
What is the phosphorylated tau interactome?
It is the set of proteins that bind phosphorylated tau, which has been mapped in human Alzheimer's disease brain and reveals disease-specific partners.
What are CSF tau MTBR fragments?
They are fragments of the tau microtubule-binding region found in cerebrospinal fluid that identify tau tangle and clinical stages of Alzheimer's disease.
Conclusion
Tau protein binding (GO:0048156) is a fundamental molecular function that governs tau's interactions with cytoskeletal, signaling, chaperone and degradation machinery. These interactions are dynamically regulated by phosphorylation and are disrupted in Alzheimer's disease, frontotemporal dementia, Down syndrome and ALS. Understanding tau protein binding requires integrating proteomic, biochemical and genetic approaches, with CRISPR models providing causal insights. EDITGENE offers a comprehensive suite of CRISPR services to accelerate research into tau protein binding and its role in neurodegeneration.
References
- 1. Parra Bravo C et al.. 2024. Cellular and pathological functions of tau.. Nat Rev Mol Cell Biol 25(11):845-864 PMID: 39014245
- 2. Horie K et al.. 2021. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.. Brain 144(2):515-527 PMID: 33283854
- 3. Roberts M et al.. 2020. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease.. Acta Neuropathol Commun 8(1):13 PMID: 32019610
- 4. Drummond E et al.. 2020. Phosphorylated tau interactome in the human Alzheimer's disease brain.. Brain 143(9):2803-2817 PMID: 32812023
- 5. Nadel CM et al.. 2024. Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP.. Nat Commun 15(1):7972 PMID: 39266525
- 6. Goedert M. 2004. Tau protein and neurodegeneration.. Semin Cell Dev Biol 15(1):45-9 PMID: 15036206
- 8. Deleon J et al.. 2018. Frontotemporal dementia.. Handb Clin Neurol 148:409-430 PMID: 29478591
